Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine
Vancouver, British Columbia–(Newsfile Corp. – August 12, 2021) – Entheon Biomedical Corp. (CNSX:ENBI.CN) (OTCQB:ENTBF) (FSE:1XU1) (” Entheon ” or the ” Company “), a biotechnology company focused on developing psychedelic medicines to treat addiction, today announced the sponsorship of a clinical research study with Heading Health LLC ( “Heading Health” ) as institution and Dr. Steve Levine, MD, as principal investigator […]
Revive Confirms No Material Undisclosed Information
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB:RVVTF) (CNSX:RVV.CN) (Frankfurt:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces that its management is not aware of any undisclosed material information relating to the Company that may be contributing to the recent increase in its […]
Cybin Announces Additional Adelia Milestone Achievements
Cybin Inc. (NEO:CYBN) (NYSEAMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-controlled subsidiary of Cybin, has achieved certain milestones for Year 1 Q3 (i)-(iii), and Year 1 Q4 (iii), as contemplated by the terms of a contribution agreement dated December […]
